Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Iron Med RX vs telos rx

By GLP-1 ScorecardUpdated

Iron Med RX
Site position #502

Lower grade

telos rx
Site position #14

Higher grade

Score comparison

telos rx has the higher recorded score — 85.4/100 to 54.8/100.

telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telos offers injectable and oral compounded GLP-1 options. Our August pricing check found that the $49 oral promotion covered the first month; renewal pricing and the prepaid billing period matter more than that headline.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valuetelos rx +42
45
87
Dose & formulationtelos rx +39
51
90
Clinical oversighttelos rx +13
71
84
Labs & monitoringtelos rx +28
52
80
Fulfillmenttelos rx +29
58
87
Contract termstelos rx +25
55
80
Iron Med RX · top bartelos rx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricIron Med RXtelos rx
WeighScore54.8/10085.4/100
GradeCB
Site position#502#14
SemaglutideNot disclosed$99/mo injectable — the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks
TirzepatideNot disclosed$139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide)
CoverageCoverage not publishedNot publicly listed
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
Iron Med RX

Site position #502 · C

Strengths

  • Unusually broad GLP-1 lineup — compounded semaglutide and tirzepatide in both oral tablets and injection, plus microdosing and longevity add-ons
  • Online process with licensed-provider oversight, virtual consults, progress tracking and home delivery
  • Oral tablet options for people who would rather not inject

What to consider

  • Prices are not shown publicly — you only see costs after creating an account, so you cannot compare value upfront
  • Labels its oral semaglutide 'research-grade' — wording usually tied to research/non-prescription peptides; confirm it is prescribed for human use
  • Does not name its compounding pharmacy or list the states it serves; the listed address is a private mailbox (PMB), not a clinic
  • Compounded GLP-1 only — no brand-name or insurance options; small, lightly documented operation
telos rx

Site position #14 · B

Strengths

  • Deep published catalog — sema, tirz, PT-141, intranasal NAD+, recovery/GH peptides, GHK-Cu, Dihexa, HRT
  • Needle-free and oral GLP-1 options, not injection-only
  • LegitScript-certified and HIPAA, with US providers and pharmacies, HSA/FSA and free shipping
  • Our August check recorded injectable semaglutide at $99/month, injectable tirzepatide at $139/month, and microdosed tirzepatide at $116/month

What to consider

  • Everything is compounded and not FDA-approved, including the peptides
  • The $49 oral offer is introductory; the recorded renewal is $129/month billed every 48 weeks. Check the total prepaid charge and renewal terms
  • No named clinicians and thin third-party reviews
  • Several research-grade peptides carry limited clinical evidence

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard